HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

galactosyl serum albumin-rhodamine green

Also Known As:

GSA-RhodG

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Albumins: 31532
    - galactosyl serum albumin-rhodamine green: 3
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Xanthenes: 65
      - Rhodamines: 466
        galactosyl serum albumin-rhodamine green: 3

Experts

1.	Choyke, Peter L: 3 articles (03/2014 - 11/2007)
2.	Kobayashi, Hisataka: 3 articles (03/2014 - 11/2007)
3.	Hanaoka, Hirofumi: 1 article (03/2014)
4.	Harada, Toshiko: 1 article (03/2014)
5.	Nakajima, Takahito: 1 article (03/2014)
6.	Sano, Kohei: 1 article (03/2014)
7.	Sato, Kazuhide: 1 article (03/2014)
8.	Watanabe, Rira: 1 article (03/2014)
9.	Kosaka, Nobuyuki: 1 article (01/2009)
10.	Longmire, Michelle R: 1 article (01/2009)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2014 - "In vivo fluorescence lifetime of GSA-RhodG stained tumors was longer than the autofluorescence lifetime (threshold, 2.87 ns). " 11/01/2007 - "In vivo optical fluorescence images of intraperitoneal tumor-bearing mice acquired 3 h after intraperitoneal injection of galactosyl serum albumin-rhodamine green successfully differentiated between tumor and normal tissue. " 11/01/2007 - "These results indicate that galactosyl serum albumin-rhodamine green can selectively target a variety of human ovarian adenocarcinomas for optical fluorescence imaging and thus may improve intraoperative tumor detection and resection." 01/01/2009 - "Both galactosyl serum albumin-rhodamine green (GSA-RhodG), which binds D-galR, and trastuzumab-Alexa680, which binds HER2/neu, were administered to tumor-bearing mice for in vivo fluorescence imaging and in situ fluorescence microscopy. "
2.	Ovarian Neoplasms (Ovarian Cancer) 03/01/2014 - "In conclusion, fluorescence-lifetime imaging with GSA-RhodG depicted ovarian cancer lesions, which were invisible in intensity images, in hemorrhagic ascites." 03/01/2014 - "Galactosyl serum albumin-rhodamine green (GSA-RhodG), which bound to the D-galactose receptor and was internalized thereafter, was administered intraperitoneally to peritoneal ovarian cancer-bearing mice with various degrees of bloody ascites. "
3.	Ascites 03/01/2014 - "In conclusion, fluorescence-lifetime imaging with GSA-RhodG depicted ovarian cancer lesions, which were invisible in intensity images, in hemorrhagic ascites." 03/01/2014 - "Galactosyl serum albumin-rhodamine green (GSA-RhodG), which bound to the D-galactose receptor and was internalized thereafter, was administered intraperitoneally to peritoneal ovarian cancer-bearing mice with various degrees of bloody ascites. "
4.	Adenocarcinoma 11/01/2007 - "Galactosyl serum albumin-rhodamine green's ability to target nine human ovarian adenocarcinoma cell lines was evaluated by flow cytometry, fluorescence microscopy and in vivo optical fluorescence imaging using female athymic nu/nu mice. " 11/01/2007 - "These results indicate that galactosyl serum albumin-rhodamine green can selectively target a variety of human ovarian adenocarcinomas for optical fluorescence imaging and thus may improve intraoperative tumor detection and resection."

Related Drugs and Biologics

1.	galactosyl serum albumin-rhodamine green
2.	Galactose (Galactopyranose)

Related Therapies and Procedures

1.	Intraperitoneal Injections